Clinical Trial Update: ABR-217620 in Combination With Docetaxel in Patients With Advanced Non-small Cell Lung Cancer [Phase 1]

View source ↗

Summary

This document reports the completion of a Phase 1 clinical trial evaluating ABR-217620 in combination with docetaxel for advanced non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ABR-217620
• DOCETAXEL (DOCETAXEL)

Snippet

Sponsor: Active Biotech AB | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 1 | Status: COMPLETED